Measurement of Staphylokinase by Enzyme-Linked Immunosorbent Assay Using Monoclonal Antibodies
スポンサーリンク
概要
- 論文の詳細を見る
Hybridoma clones producing monoclonal antibodies specific for staphylokinase were isolated. A competitive assay revealed that the monoclonal antibodies studied could be divided into at least two groups. Representatives of these groups, AS22 and B3E6,recognized quite different epitopes on staphylokinase. This finding led us to develop an assay system for the quantitative analysis of staphylokinase by enzyme-linked immunosorbent assay using AS22 as the capturing antibody and biotinylated B3E6 as the "detector". The lower limit of sensitivity of the assay was 20 pg of staphylokinase per ml. The assay exhibited good reproducibility, with values of 5.8 and 3.8% for the intra-and inter-assay coefficients of variation, respectively. Staphylokinase could be assayed in the presence of human plasma when the plasma was diluted more than 320-fold, and the measurement was unaffected by the presence of physiological concentrations of human plasminogen. Hence, this assay was considered useful for the detection and quantification of staphylokinase in clinical samples.
- 社団法人日本薬学会の論文
- 1994-05-15
著者
-
横倉 輝男
ヤクルト中央研究所
-
酒井 正士
Yakult Central Institute For Microbiological Research
-
横倉 輝男
Yakult Central Institute for Microbiological Research
-
三毛 明人
Yakult Central Institute for Microbiological Research
-
大矢 陽子
Yakult Central Institute for Microbiological Research
-
大脇 眞
Yakult Central Institute for Microbiological Research
-
左古 知行
Yakult Central Institute for Microbiological Research
-
渡辺 常一
Yakult Central Institute for Microbiological Research
-
横倉 輝雄
Yakult Institute for Microbiological Research
-
横倉 輝男
ヤクルト本社 中研
-
横倉 輝男
Yakult Central Institute
関連論文
- 乳酸桿菌の自然免疫系賦活作用の解析
- LACTOBACILLUS CACEIのラット膀胱発癌に対する影響
- Involvement of Protease Inhibitors in Staphylokinase-Induced Fibrin-Specific Fibrinolysis
- Fibrin-Specific Fibrinolysis Induced by Recombinant Staphylokinase
- Measurement of Staphylokinase by Enzyme-Linked Immunosorbent Assay Using Monoclonal Antibodies
- 453 Streptomyces sp. C-51株由来のコラゲナーゼの生産条件および性質について
- Chemical Modification of Antitumor Alkaloids, 20(S)-Camptothecin and 7-Ethylcamptothecin : Reaction of the E-Lactone Ring Portion with Hydrazine Hydrate
- カンプトテシン誘導体の合成および抗腫瘍活性 : 7-エチル-10-ヒドロキシカンプトテシンの水溶性カルバメート誘導体(発表論文抄録(1991年))
- Synthesis and Antitumor Activity of 20(S)-Camptothecin Derivatives : Carbamate-Linked, Water-Soluble Derivaties of 7-Ethyl-10-hydroxycamptothecin
- 家蚕微胞子虫類胞子に対する単クロ-ン抗体の作製
- モズクフコイダンおよびウロン酸含有多糖の蛍光標識法およびHPLC分析法の検討
- モズク由来フコイダンの抗潰瘍効果について : 生体高分子・脂質
- モズク由来フコイダンの構造とHelicobactor pyloriに対する定着阻害作用について : 生体高分子・脂質
- Anti-ulcer Effects of Lactic Acid Bacteria and Their Cell Wall Polysaccharides
- Synthesis and Antitumor Activity of 20(S)-Camptothecin Derivatives. A-Ring-Substituted 7-Ethylcamptothecins and Their E-Ring-Modified Water-Soluble Derivatives
- Synthesis and Antiumor Activity of 20(S)-Camptothecin Derivatives : A-Ring Modified and 7,10-Disubstituted Camptothecins
- Chemical Modification of an Antitumor Alkaloid, 20(S)-Camptothecin : E-Lactone Ring-Modified Water-Soluble Derivatives of 7-Ethylcamptothecin
- Determination of Self-Association of Irinotecan Hydrochloride (CPT-11) in Aqueous Solution
- Chemical Modification of an Antitumor Alkaloid, 20(S)-Camptothecin : Glycosides, Phosphates and Sulfates of 7-Ethyl 10-hydroxycamptothecin
- Chemical Modification of an Antitumor Alkaloid Camprothecin : Synthesis and Antitumor Activity of 7-C-Substituted Camptothecins
- Studies on Non-sesquiterpenoid Constituents of Gaillardia pulchella. II. Less Lipophilic Substances, Methyl Caffeate as an Antitumor Catecholic
- Tyrosinase Inhibitors from Crude Drugs
- 乳酸菌による予防医学をめざして (あゆみ 食から薬へ)
- アセクロフェナクの細胞内ターゲット抗炎症効果
- 単クロ-ン抗体感作ラテックスによる蚕微粒子病診断の試み
- 家蚕細胞質多角体病ウイルスに対する単クロ-ン抗体の作製
- Mitogenic Effect of lactobacilli on Murine Lymphocytes
- Corynebacterium parvum, BCG, OK-432およびLactobacillus caseiのマウス肝薬物代謝酵素と肝マクロファージの活性酸素生成能におよぼす影響
- 乳酸菌溶解酵素の性質
- Target anti-inflammatory effects in aceclofecna cells.
- Chemotherapy of malignant tumor viewed from pharmacodynamics of antitumor medicines.5.Pharmacokinetics of topoisomerase inhibitor and antitumor effect.